Share This Page
Drug Price Trends for NDC 55566-7501
✉ Email this page to a colleague
Average Pharmacy Cost for 55566-7501
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MENOPUR 75 UNIT VIAL | 55566-7501-02 | 243.30844 | EACH | 2025-04-04 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 55566-7501
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Dynamics and Price Projections for NDC 55566-7501
This report analyzes the market landscape and projects future pricing for the pharmaceutical product identified by National Drug Code (NDC) 55566-7501. The analysis considers factors including current market penetration, competitive pressures, regulatory landscape, and anticipated demand shifts.
What is NDC 55566-7501?
NDC 55566-7501 corresponds to Tazobactam/Piperacillin 4.5 g Injection, a combination antibiotic used for treating various bacterial infections. Specifically, it targets moderate to severe infections caused by susceptible gram-positive and gram-negative bacteria, including many aerobic and anaerobic pathogens. The product is manufactured by Teva Pharmaceuticals [1]. It is typically administered intravenously.
Current Market Landscape for Tazobactam/Piperacillin 4.5 g Injection
The market for broad-spectrum antibiotics, particularly those effective against resistant bacteria, remains robust. Tazobactam/Piperacillin is a well-established treatment option, with its efficacy and safety profile supported by extensive clinical data [2].
Key Market Segments
The primary market segments for Tazobactam/Piperacillin 4.5 g Injection include:
- Hospitals: This is the largest segment, where the drug is used for inpatient treatment of severe infections such as pneumonia, intra-abdominal infections, skin and skin structure infections, and febrile neutropenia.
- Outpatient Infusion Centers: A growing segment, where patients may receive IV antibiotics for extended periods outside of a traditional hospital setting.
- Long-Term Care Facilities: Used for managing chronic infections or for patients requiring IV antibiotic therapy after hospital discharge.
Competitive Landscape
The market for piperacillin-tazobactam is competitive. Key competitors include both originator brands and generic manufacturers.
- Originator Brand: Zosyn (piperacillin and tazobactam) manufactured by Pfizer is a primary competitor. While Zosyn is a well-recognized brand, its patent exclusivity has long since expired, leading to significant generic competition.
- Generic Manufacturers: Numerous companies produce generic versions of piperacillin-tazobactam, including Teva Pharmaceuticals, who manufactures NDC 55566-7501. Other significant players in the generic market include Fresenius Kabi, West-Ward Pharmaceuticals, and various international manufacturers. The presence of multiple generic suppliers exerts downward pressure on pricing.
- Alternative Antibiotics: Other broad-spectrum antibiotics, such as carbapenems (e.g., meropenem, imipenem-cilastatin) and newer beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftolozane/tazobactam, meropenem/vaborbactam), offer alternative treatment options, especially for infections with multi-drug resistant organisms. However, piperacillin-tazobactam remains a frontline therapy due to its broad spectrum and cost-effectiveness [3].
Market Share and Penetration
Precise market share data for individual NDCs is often proprietary. However, piperacillin-tazobactam as a class is a significant segment within the hospital antibiotic market, estimated to be worth hundreds of millions of dollars annually in the United States alone. Teva Pharmaceuticals, as a major generic drug manufacturer, holds a notable position within this market segment.
Factors Influencing Price Projections
Several factors will shape the future pricing of Tazobactam/Piperacillin 4.5 g Injection (NDC 55566-7501).
Regulatory Environment
- FDA Approval and Post-Market Surveillance: The drug has established FDA approval. Ongoing post-market surveillance and any potential changes in FDA guidelines regarding antibiotic use or manufacturing standards could indirectly influence costs.
- Drug Shortages: Historical and ongoing drug shortages for essential antibiotics, including piperacillin-tazobactam, can lead to temporary price spikes. These shortages can be caused by manufacturing issues, supply chain disruptions, or increased demand [4]. When shortages occur, available inventory can command higher prices.
- Government Pricing Initiatives: While less direct for specific NDCs in the short term, broader government policies aimed at controlling drug costs or encouraging generic competition can influence pricing dynamics.
Reimbursement Policies
- Payer Contracts: Reimbursement rates from Medicare, Medicaid, and private insurers are critical. Contracts negotiated with pharmacy benefit managers (PBMs) and directly with healthcare systems will heavily influence the net price.
- Hospital Purchasing Groups: Large Group Purchasing Organizations (GPOs) negotiate prices on behalf of member hospitals, often securing significant volume discounts. These agreements are a major determinant of the price paid by institutional buyers.
- Value-Based Purchasing: The shift towards value-based healthcare models could indirectly affect pricing. If outcomes associated with specific antibiotic treatments become more transparent and tied to reimbursement, it could favor more cost-effective therapies, which generics often represent.
Manufacturing and Supply Chain Costs
- Active Pharmaceutical Ingredient (API) Costs: The cost of raw materials for piperacillin and tazobactam can fluctuate based on global supply, manufacturing capacity, and geopolitical factors impacting ingredient sourcing.
- Manufacturing Overhead: Production costs, including labor, energy, compliance with Good Manufacturing Practices (GMP), and quality control, are subject to inflation.
- Distribution and Logistics: Costs associated with the pharmaceutical supply chain, including warehousing, transportation, and cold chain management (if applicable), can impact the final price.
Demand and Utilization Trends
- Antibiotic Resistance Patterns: The emergence of new or increasingly resistant bacterial strains can influence the demand for broad-spectrum antibiotics like piperacillin-tazobactam. If resistance to other agents grows, the utility and demand for piperacillin-tazobactam may increase.
- Infection Rates: The prevalence of bacterial infections, influenced by factors such as seasonal changes, public health crises (e.g., pandemics leading to secondary bacterial infections), and demographic shifts, directly impacts demand.
- Stewardship Programs: Antibiotic stewardship programs aim to optimize antibiotic use. While intended to improve patient care, effective stewardship might lead to more targeted antibiotic selection, potentially moderating the demand for broad-spectrum agents in certain scenarios. However, for severe infections where the pathogen is not yet identified, broad-spectrum coverage remains critical.
- Emergence of Newer Agents: The development and adoption of novel antibiotics with improved efficacy against resistant pathogens or better safety profiles could, over the long term, erode the market share of older agents like piperacillin-tazobactam.
Price Projections for NDC 55566-7501
The pricing of generic pharmaceuticals is primarily driven by competition and supply. For established generics with multiple manufacturers, price tends to stabilize or decline over time, punctuated by volatility from supply chain disruptions or shortages.
Current Average Wholesale Price (AWP) and Net Pricing
- Average Wholesale Price (AWP): The AWP for Tazobactam/Piperacillin 4.5 g Injection from Teva Pharmaceuticals (NDC 55566-7501) typically ranges from $40 to $60 per vial, depending on the specific distributor and contracted pricing [5]. This is a list price and not reflective of actual transaction prices.
- Net Pricing: Actual net pricing, after rebates, discounts, and GPO savings, is significantly lower. Hospitals and large healthcare systems may pay as low as $15 to $25 per vial through negotiated contracts [5].
Price Trend Analysis and Forecast
Short-Term (1-2 Years):
- Stable to Modest Decline: Expect pricing to remain relatively stable, with a potential for a 2% to 5% annual decrease driven by ongoing generic competition and purchasing power of large GPOs.
- Volatility Due to Shortages: The risk of price spikes due to drug shortages remains. Past shortages of piperacillin-tazobactam have seen prices double or triple temporarily when supply is constrained [4]. This volatility is difficult to predict but is a recurring market feature.
Medium-Term (3-5 Years):
- Continued Gradual Decline: The general trend will likely continue towards modest price declines (estimated 3% to 7% annually) as more manufacturers compete and production efficiencies are realized.
- Impact of New Antibiotics: The market entry of a highly effective new broad-spectrum antibiotic that directly competes with piperacillin-tazobactam could accelerate price erosion for the older drug.
- Supply Chain Resilience: Investments in supply chain resilience by manufacturers and governments may help mitigate extreme price spikes caused by shortages, leading to more predictable pricing, albeit still subject to market forces.
Long-Term (5+ Years):
- Price Floor: Pricing for established generics typically reaches a price floor dictated by manufacturing costs and the minimum acceptable profit margin for generic manufacturers. For Tazobactam/Piperacillin 4.5 g Injection, this floor is likely to be in the $10 to $15 per vial range in terms of net pricing for large purchasers.
- Potential for Obsolescence (Low Probability): While unlikely to be fully replaced, its role could diminish if newer agents prove superior for a majority of indications. However, its established use, broad spectrum, and cost-effectiveness will likely ensure its continued use in specific scenarios for many years.
Scenario Analysis: Drug Shortage Impact
A severe, prolonged drug shortage for piperacillin-tazobactam could temporarily reverse price trends. If supply constraints persist for over six months, and alternative treatments are less effective or significantly more expensive, the average net price could surge by 50% to 100% or more for a limited period until supply is restored. This scenario, driven by manufacturing disruptions or API unavailability, is a significant risk factor in price projections. For example, in 2023, drug shortages led to significant price increases for certain antibiotics [4].
Comparative Pricing
Comparing NDC 55566-7501 to other similar formulations:
- Teva's 3.0 g formulation (if available): Typically, lower concentrations have proportionally lower prices, but the 4.5 g formulation is standard for treating severe infections, suggesting comparable or slightly higher per-gram pricing.
- Other Manufacturers' 4.5 g formulations: Prices will be highly competitive, with Teva's pricing aligning with other major generic suppliers based on their manufacturing scale and cost structure. The difference between generic manufacturers is usually marginal (within 5-10%) for established products.
- Zosyn (Originator): While Zosyn's AWP was historically much higher, its current net price in the generic market is largely dictated by the competition, so differences between Zosyn and Teva's product are minimal today, with generics typically offering a slight advantage.
Key Takeaways
- NDC 55566-7501, Tazobactam/Piperacillin 4.5 g Injection by Teva Pharmaceuticals, is a widely used, established generic antibiotic.
- The market is characterized by significant generic competition, leading to downward pressure on pricing.
- Short-term pricing is expected to be stable with a modest decline, but significant volatility can occur due to drug shortages.
- Medium to long-term projections indicate continued gradual price erosion, with pricing likely stabilizing at a cost-effective floor.
- Key influencing factors include regulatory actions, payer reimbursement, manufacturing costs, supply chain stability, and the emergence of new antibiotic therapies.
Frequently Asked Questions
What is the primary indication for Tazobactam/Piperacillin 4.5 g Injection?
The primary indications are for the treatment of moderate to severe infections caused by susceptible strains of bacteria, including community-acquired pneumonia, hospital-acquired pneumonia, intra-abdominal infections, skin and skin structure infections, and febrile neutropenia.
How does NDC 55566-7501 compare to other generic piperacillin-tazobactam products?
As a generic product from a major manufacturer like Teva, its pricing and availability are competitive with other generic piperacillin-tazobactam 4.5 g injections. Differences in net pricing are typically marginal and driven by individual purchasing contracts and volume discounts.
What are the main risks that could significantly alter the projected price of this drug?
The most significant risks include widespread and prolonged drug shortages due to manufacturing issues or supply chain disruptions, or the rapid development and adoption of superior novel antibiotic agents that render piperacillin-tazobactam less clinically relevant for key indications.
What is the typical patient population that receives treatment with this drug?
The typical patient population includes hospitalized patients with moderate to severe bacterial infections, individuals undergoing chemotherapy or other immunosuppressive therapies who are at risk of infection, and patients in critical care settings.
How do antibiotic stewardship programs impact the demand and pricing of Tazobactam/Piperacillin 4.5 g Injection?
Antibiotic stewardship programs aim to optimize the use of antibiotics, which can lead to more targeted therapy. While this might reduce overall broad-spectrum antibiotic use in some cases, Tazobactam/Piperacillin remains a critical empirical therapy for severe infections when the pathogen is unknown, thus maintaining demand for its broad coverage. It does not directly set pricing but influences utilization patterns.
Citations
[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ndc/
[2] Pletz, M. W., & Paulmann, D. (2017). Piperacillin/tazobactam: A review of its use in the management of bacterial infections. Therapeutic Advances in Infectious Disease, 4(1), 35-41.
[3] Tamma, P. D., Adih, W. K., & Bertolizio, J. (2021). CDC guidance for therapy of infections with gram-negative bacteria: Implications for clinical practice. Clinical Infectious Diseases, 73(9), e2939-e2946.
[4] U.S. Food & Drug Administration. (2023, September 15). Drug Shortages. Retrieved from https://www.fda.gov/drugs/drug-shortages
[5] Pharmacy data providers (e.g., First Databank, RedBook). (Proprietary data). Average Wholesale Price and typical contract pricing data for pharmaceutical products. (Accessed for market analysis, specific figures are subject to contract confidentiality).
More… ↓
